Marksans Pharma Ltd (MARKSANS) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 604869,
    "name": "Marksans Pharma",
    "stock_name": "Marksans Pharma",
    "full_name": "Marksans Pharma Ltd",
    "name_url": "stocks-analysis/marksans-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "185.60",
    "chg": -2.3,
    "chgp": "-1.22%",
    "dir": -1,
    "prev_price": "187.90",
    "mcapval": "8,410.72 Cr",
    "mcap": "Small Cap",
    "scripcode": 524404,
    "symbol": "MARKSANS",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE750C01026",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": "2.75 lacs",
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/marksans-pharma-604869-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Marksans Pharma Sees Revision in Market Evaluation Amidst Challenging Sector Dynamics",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/marksans-pharma-downgraded-to-sell-by-marketsmojo-amid-weak-financial-and-technical-signals-3733204",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/MarksansPharma_mojoScore_3733204.png",
        "date": "2025-11-27 10:05:56",
        "description": "Marksans Pharma has undergone a revision in its market evaluation, reflecting shifts in key analytical parameters that influence investor perception. This adjustment highlights evolving views on the company’s financial trends, valuation, technical outlook, and overall quality within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Marksans Pharma Q2 FY26: Strong Quarter Masks Underlying Concerns as FII Exit Continues",
        "link": "https://www.marketsmojo.com/news/result-analysis/marksans-pharma-q2-fy26-strong-quarter-masks-underlying-concerns-as-fii-exit-continues-3716608",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/MarksansPharma_quaterlyResult_3716608.png",
        "date": "2025-11-15 10:03:51",
        "description": "Marksans Pharma Ltd., a Mumbai-based pharmaceutical formulation manufacturer, reported a consolidated net profit of ₹98.25 crores for Q2 FY26, marking a robust 68.47% quarter-on-quarter surge from ₹58.32 crores in Q1 FY26. However, the year-on-year picture remains subdued, with profits growing just 1.58% from ₹96.72 crores in Q2 FY25. The ₹8,712 crore market capitalisation company's shares have faced persistent selling pressure, declining 37.30% over the past year despite the recent quarterly uptick, as foreign institutional investors continue reducing their stake."
      },
      {
        "title": "How has been the historical performance of Marksans Pharma?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-marksans-pharma-3703554",
        "imagepath": "",
        "date": "2025-11-15 00:04:52",
        "description": "Answer:\nThe historical performance of Marksans Pharma shows a consistent growth trajectory in key financial metrics over the years.\n\nBreakdown:\nMarksans Pharma's net sales have steadily increased from INR 1,134.21 crore in March 2020 to INR 2,622.85 crore in March 2025, reflecting a strong upward trend. Total operating income has followed a similar pattern, rising from INR 1,000.07 crore in March 2019 to INR 2,622.85 crore in March 2025. The company's total expenditure, excluding depreciation, also grew significantly, reaching INR 2,090.16 crore in March 2025, up from INR 941.96 crore in March 2020. Operating profit (PBDIT) has shown a positive trend, increasing from INR 192.25 crore in March 2020 to INR 599.02 crore in March 2025, although the operating profit margin slightly decreased from 21.06% in March 2024 to 20.31% in March 2025. Profit before tax rose from INR 157.17 crore in March 2020 to INR 503.9..."
      },
      {
        "title": "Is Marksans Pharma technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-marksans-pharma-technically-bullish-or-bearish-3700298",
        "imagepath": "",
        "date": "2025-11-14 08:12:23",
        "description": "As of 13 November 2025, the technical trend for Marksans Pharma has changed from sideways to mildly bearish. The current stance is bearish, with key indicators driving this assessment including the daily moving averages showing a mildly bearish trend and the Bollinger Bands indicating a mildly bearish position on both weekly and monthly time frames. Although the weekly MACD and KST are mildly bullish, the overall monthly indicators, including MACD and KST, are mildly bearish, reinforcing the bearish sentiment. The RSI on the weekly is bullish but lacks confirmation from the monthly signal, contributing to a mixed outlook. Overall, the strength of the bearish trend is moderate, influenced by the recent price action and the broader context of the stock's performance compared to the Sensex...."
      },
      {
        "title": "Marksans Pharma Experiences Mixed Technical Signals Amid Market Volatility",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/marksans-pharmas-technical-trend-shifts-from-sideways-to-mildly-bearish-amid-stock-decline-3700593",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/MarksansPharma_technicaldot_3700593.png",
        "date": "2025-11-14 08:05:55",
        "description": "Marksans Pharma has experienced recent stock price fluctuations, currently priced at 187.00. The company shows mixed technical indicators, with some suggesting bullish momentum while others indicate bearish trends. Despite recent declines in year-to-date and one-year returns, the stock has demonstrated substantial growth over three and five years."
      },
      {
        "title": "How has been the historical performance of Marksans Pharma?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-marksans-pharma-3699396",
        "imagepath": "",
        "date": "2025-11-13 23:35:04",
        "description": "Answer:\nThe historical performance of Marksans Pharma shows a consistent growth trend in net sales and profitability over the years.\n\nBreakdown:\nMarksans Pharma has demonstrated significant growth in net sales, increasing from 1,000.07 Cr in Mar'19 to 2,622.85 Cr in Mar'25. This upward trajectory reflects a steady rise in total operating income, which also grew from 1,000.07 Cr in Mar'19 to 2,622.85 Cr in Mar'25. The company's operating profit, excluding other income, rose from 132.14 Cr in Mar'19 to 532.69 Cr in Mar'25, indicating improved operational efficiency. Profit before tax followed a similar trend, climbing from 104.31 Cr in Mar'19 to 503.97 Cr in Mar'25, while profit after tax increased from 80.44 Cr to 382.62 Cr over the same period. The earnings per share (EPS) also improved significantly, reaching 8.4 in Mar'25 compared to 1.97 in Mar'19. On the balance sheet, total assets grew from 902.03 Cr i..."
      },
      {
        "title": "Is Marksans Pharma technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-marksans-pharma-technically-bullish-or-bearish-3696357",
        "imagepath": "",
        "date": "2025-11-13 08:14:38",
        "description": "As of 12 November 2025, the technical trend for Marksans Pharma has changed from mildly bearish to sideways. The current stance is neutral, with mixed signals across different time frames. The weekly MACD is mildly bullish, while the monthly MACD is mildly bearish. The weekly RSI indicates bullish momentum, but the monthly RSI shows no signal. Moving averages on a daily basis are mildly bearish, contrasting with the weekly and monthly KST and Dow Theory, which are both mildly bullish. Overall, the indicators suggest a lack of clear direction, with strength in weekly signals but weakness in monthly assessments...."
      },
      {
        "title": "Marksans Pharma Faces Mixed Technical Trends Amidst Market Volatility and Evaluation Revision",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/marksans-pharmas-technical-trend-shifts-from-mildly-bearish-to-sideways-amid-stock-price-increase-3696535",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/MarksansPharma_technicaldot_3696535.png",
        "date": "2025-11-13 08:06:46",
        "description": "Marksans Pharma, a small-cap pharmaceutical company, has seen notable stock price fluctuations, with a current price of 196.60. The stock has experienced significant volatility over the past year, with a 52-week high of 358.50 and a low of 162.05, reflecting its dynamic market position."
      },
      {
        "title": "Why is Marksans Pharma falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-marksans-pharma-fallingrising-3690958",
        "imagepath": "",
        "date": "2025-11-11 22:58:07",
        "description": "As of 11-Nov, Marksans Pharma Ltd is experiencing a rise in its stock price, currently at Rs 194.40, reflecting an increase of Rs 7.35 or 3.93%. The stock has shown a positive performance today, outperforming its sector by 4.06%, and has gained 6.37% over the last two days. Despite touching an intraday high of Rs 196.5, the stock's trading volume indicates a decline in investor participation, with a 9.04% drop in delivery volume compared to the 5-day average. While the stock has performed well in the short term, with a 4.10% increase over the past week and a 7.08% increase over the past month, it has significantly underperformed on a year-to-date basis with a decline of 34.38%. The company maintains a high management efficiency with a return on equity (ROE) of 17.66% and a low debt-to-equity ratio, which may contribute positively to investor sentiment.\n\nIn the broader market context, the stock's recent perf..."
      }
    ],
    "total": 304,
    "sid": "604869",
    "stock_news_url": "https://www.marketsmojo.com/news/marksans-pharma-604869"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
      "datetime": "21-Nov-2025",
      "details": "Marksans Pharma Limited submits Transcript of Investors/analysts meet on Q2 FY26 Unaudited Financial Results held on November 14 2025 at 05:00 pm.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
      "datetime": "20-Nov-2025",
      "details": "Marksans Pharma Limiteds wholly owned subsidiary Relonchem Limited receives Marketing Authorisation for its product Cetirizine Dihydrochloride 1 mg/ml oral solution from UK MHRA.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
      "datetime": "19-Nov-2025",
      "details": "Marksans Pharma Limiteds wholly owned subsidiary Marksans Pharma Inc receives US FDA approval of its ANDA for Loperamide Hydrochloride 2mg tablets.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Marksans Pharma Ltd has declared <strong>80%</strong> dividend, ex-date: 01 Aug 25",
          "dt": "2025-08-01",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Marksans Pharma Ltd has announced <strong>1:10</strong> stock split, ex-date: 11 Mar 08",
          "dt": "2008-03-11",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Marksans Pharma Sees Revision in Market Evaluation Amidst Challenging Sector Dynamics

2025-11-27 10:05:56

Marksans Pharma has undergone a revision in its market evaluation, reflecting shifts in key analytical parameters that influence investor perception. This adjustment highlights evolving views on the company’s financial trends, valuation, technical outlook, and overall quality within the Pharmaceuticals & Biotechnology sector.

Marksans Pharma Q2 FY26: Strong Quarter Masks Underlying Concerns as FII Exit Continues

2025-11-15 10:03:51

Marksans Pharma Ltd., a Mumbai-based pharmaceutical formulation manufacturer, reported a consolidated net profit of ₹98.25 crores for Q2 FY26, marking a robust 68.47% quarter-on-quarter surge from ₹58.32 crores in Q1 FY26. However, the year-on-year picture remains subdued, with profits growing just 1.58% from ₹96.72 crores in Q2 FY25. The ₹8,712 crore market capitalisation company's shares have faced persistent selling pressure, declining 37.30% over the past year despite the recent quarterly uptick, as foreign institutional investors continue reducing their stake.

How has been the historical performance of Marksans Pharma?

2025-11-15 00:04:52

Answer: The historical performance of Marksans Pharma shows a consistent growth trajectory in key financial metrics over the years. Breakdown: Marksans Pharma's net sales have steadily increased from INR 1,134.21 crore in March 2020 to INR 2,622.85 crore in March 2025, reflecting a strong upward trend. Total operating income has followed a similar pattern, rising from INR 1,000.07 crore in March 2019 to INR 2,622.85 crore in March 2025. The company's total expenditure, excluding depreciation, also grew significantly, reaching INR 2,090.16 crore in March 2025, up from INR 941.96 crore in March 2020. Operating profit (PBDIT) has shown a positive trend, increasing from INR 192.25 crore in March 2020 to INR 599.02 crore in March 2025, although the operating profit margin slightly decreased from 21.06% in March 2024 to 20.31% in March 2025. Profit before tax rose from INR 157.17 crore in March 2020 to INR 503.9...

Is Marksans Pharma technically bullish or bearish?

2025-11-14 08:12:23

As of 13 November 2025, the technical trend for Marksans Pharma has changed from sideways to mildly bearish. The current stance is bearish, with key indicators driving this assessment including the daily moving averages showing a mildly bearish trend and the Bollinger Bands indicating a mildly bearish position on both weekly and monthly time frames. Although the weekly MACD and KST are mildly bullish, the overall monthly indicators, including MACD and KST, are mildly bearish, reinforcing the bearish sentiment. The RSI on the weekly is bullish but lacks confirmation from the monthly signal, contributing to a mixed outlook. Overall, the strength of the bearish trend is moderate, influenced by the recent price action and the broader context of the stock's performance compared to the Sensex....

Marksans Pharma Experiences Mixed Technical Signals Amid Market Volatility

2025-11-14 08:05:55

Marksans Pharma has experienced recent stock price fluctuations, currently priced at 187.00. The company shows mixed technical indicators, with some suggesting bullish momentum while others indicate bearish trends. Despite recent declines in year-to-date and one-year returns, the stock has demonstrated substantial growth over three and five years.

How has been the historical performance of Marksans Pharma?

2025-11-13 23:35:04

Answer: The historical performance of Marksans Pharma shows a consistent growth trend in net sales and profitability over the years. Breakdown: Marksans Pharma has demonstrated significant growth in net sales, increasing from 1,000.07 Cr in Mar'19 to 2,622.85 Cr in Mar'25. This upward trajectory reflects a steady rise in total operating income, which also grew from 1,000.07 Cr in Mar'19 to 2,622.85 Cr in Mar'25. The company's operating profit, excluding other income, rose from 132.14 Cr in Mar'19 to 532.69 Cr in Mar'25, indicating improved operational efficiency. Profit before tax followed a similar trend, climbing from 104.31 Cr in Mar'19 to 503.97 Cr in Mar'25, while profit after tax increased from 80.44 Cr to 382.62 Cr over the same period. The earnings per share (EPS) also improved significantly, reaching 8.4 in Mar'25 compared to 1.97 in Mar'19. On the balance sheet, total assets grew from 902.03 Cr i...

Is Marksans Pharma technically bullish or bearish?

2025-11-13 08:14:38

As of 12 November 2025, the technical trend for Marksans Pharma has changed from mildly bearish to sideways. The current stance is neutral, with mixed signals across different time frames. The weekly MACD is mildly bullish, while the monthly MACD is mildly bearish. The weekly RSI indicates bullish momentum, but the monthly RSI shows no signal. Moving averages on a daily basis are mildly bearish, contrasting with the weekly and monthly KST and Dow Theory, which are both mildly bullish. Overall, the indicators suggest a lack of clear direction, with strength in weekly signals but weakness in monthly assessments....

Marksans Pharma Faces Mixed Technical Trends Amidst Market Volatility and Evaluation Revision

2025-11-13 08:06:46

Marksans Pharma, a small-cap pharmaceutical company, has seen notable stock price fluctuations, with a current price of 196.60. The stock has experienced significant volatility over the past year, with a 52-week high of 358.50 and a low of 162.05, reflecting its dynamic market position.

Why is Marksans Pharma falling/rising?

2025-11-11 22:58:07

As of 11-Nov, Marksans Pharma Ltd is experiencing a rise in its stock price, currently at Rs 194.40, reflecting an increase of Rs 7.35 or 3.93%. The stock has shown a positive performance today, outperforming its sector by 4.06%, and has gained 6.37% over the last two days. Despite touching an intraday high of Rs 196.5, the stock's trading volume indicates a decline in investor participation, with a 9.04% drop in delivery volume compared to the 5-day average. While the stock has performed well in the short term, with a 4.10% increase over the past week and a 7.08% increase over the past month, it has significantly underperformed on a year-to-date basis with a decline of 34.38%. The company maintains a high management efficiency with a return on equity (ROE) of 17.66% and a low debt-to-equity ratio, which may contribute positively to investor sentiment. In the broader market context, the stock's recent perf...

View All News